Cencora (NYSE:COR) Price Target Cut to $339.00 by Analysts at Robert W. Baird

Cencora (NYSE:COR) had its price target cut by Robert W. Baird from $420.00 to $339.00 in a research note published on Thursday,Benzinga reports. They currently have an outperform rating on the stock.

Other analysts have also recently issued research reports about the company. JPMorgan Chase & Co. raised their price objective on Cencora from $417.00 to $419.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 10th. Evercore set a $360.00 price target on shares of Cencora in a report on Wednesday, April 8th. Leerink Partners reissued an “outperform” rating on shares of Cencora in a report on Tuesday, March 17th. Weiss Ratings reissued a “buy (b)” rating on shares of Cencora in a research note on Monday. Finally, Morgan Stanley set a $380.00 price target on shares of Cencora in a research note on Tuesday, March 17th. Twelve investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $388.42.

Cencora Trading Up 3.5%

Shares of NYSE:COR traded up $8.95 on Thursday, hitting $264.61. 886,508 shares of the company’s stock were exchanged, compared to its average volume of 1,436,694. Cencora has a 12 month low of $244.82 and a 12 month high of $377.54. The stock has a market capitalization of $51.47 billion, a price-to-earnings ratio of 20.28, a price-to-earnings-growth ratio of 1.18 and a beta of 0.64. The business’s 50 day simple moving average is $327.81 and its two-hundred day simple moving average is $342.26. The company has a debt-to-equity ratio of 3.40, a current ratio of 0.95 and a quick ratio of 0.51.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $4.75 EPS for the quarter, missing analysts’ consensus estimates of $4.82 by ($0.07). The company had revenue of $78.36 billion during the quarter, compared to the consensus estimate of $81.09 billion. Cencora had a return on equity of 135.20% and a net margin of 0.78%.The company’s revenue for the quarter was up 3.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.42 earnings per share. Cencora has set its FY 2026 guidance at 17.650-17.900 EPS. Analysts anticipate that Cencora will post 17.58 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, June 1st. Investors of record on Friday, May 15th will be issued a $0.60 dividend. The ex-dividend date of this dividend is Friday, May 15th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.9%. Cencora’s dividend payout ratio is currently 28.85%.

Institutional Trading of Cencora

Several hedge funds have recently made changes to their positions in COR. Kemnay Advisory Services Inc. purchased a new position in Cencora in the fourth quarter worth approximately $25,000. Oakworth Capital Inc. purchased a new position in shares of Cencora during the 4th quarter worth $26,000. Elyxium Wealth LLC acquired a new stake in shares of Cencora during the 4th quarter worth about $27,000. Archer Investment Corp raised its holdings in Cencora by 134.3% in the 4th quarter. Archer Investment Corp now owns 82 shares of the company’s stock valued at $28,000 after buying an additional 47 shares during the period. Finally, Motiv8 Investments LLC acquired a new position in Cencora in the fourth quarter valued at about $29,000. Hedge funds and other institutional investors own 97.52% of the company’s stock.

About Cencora

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.